Clinical Trial Update: Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a new Leuprolide Acetate 17 mg depot for prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Leuprolide Acetate 17 mg Depot (Leuprolide acetate)

Snippet

Sponsor: GP-Pharm | Conditions: Prostate Cancer | Phase 3 | Status: TERMINATED